Related references
Note: Only part of the references are listed.Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
Shaheen Khan et al.
SEMINARS IN CANCER BIOLOGY (2020)
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
Patrick J. Engelberts et al.
EBIOMEDICINE (2020)
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
Ugur Eskiocak et al.
JCI INSIGHT (2020)
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Christina L. Zuch de Zafra et al.
CLINICAL CANCER RESEARCH (2019)
Bispecific Antibodies in the Treatment of Hematologic Malignancies
Johannes Duell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Immunotherapy in pediatric B-cell acute lymphoblastic leukemia
Kirk D. Wyatt et al.
HUMAN IMMUNOLOGY (2019)
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Nathan D. Trinklein et al.
MABS (2019)
Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow
Raoufeh Ahamadi-Fesharaki et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343
Marlon J. Hinner et al.
CLINICAL CANCER RESEARCH (2019)
Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs
Laahn H. Foster et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.
Jermaine Coward et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
Xinyue Qi et al.
NATURE COMMUNICATIONS (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
A FIRST-IN-HUMAN STUDY OF A HALF-LIFE EXTENDED CD19-TARGETING BiTE IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA OR FOLLICULAR LYMPHOMA
L. Popplewell et al.
HEMATOLOGICAL ONCOLOGY (2019)
Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma
Tatsushi Kodama et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Christina Claus et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
Kasper Mikkelsen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
Peter Valent et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Siler H. Panowski et al.
MOLECULAR CANCER THERAPEUTICS (2019)
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
Ji Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
AMG 701, a half-life extended anti-BCMA BiTE®, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment
Shih-Feng Cho et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
Luciano J. Costa et al.
BLOOD (2019)
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Stephen J. Schuster et al.
BLOOD (2019)
Engineering therapeutic bispecific antibodies using CrossMab technology
Christian Klein et al.
METHODS (2019)
A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats
Gregory L. Moore et al.
METHODS (2019)
Immune checkpoint inhibitor-related myocarditis
Kazuko Tajiri et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies
Thomas Van Blarcom et al.
MABS (2018)
CD20-selective inhibition of CD47-SIRP alpha don't eat me signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
Peter E. van Bommel et al.
ONCOIMMUNOLOGY (2018)
Bispecific antibody based therapeutics: Strengths and challenges
Archana Thakur et al.
BLOOD REVIEWS (2018)
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
Cecile A. W. Geuijen et al.
CANCER CELL (2018)
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2018)
A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies
Gregory Z. Ferl et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Haitao Pan et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
Joshua Ryan Richter et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chronic lymphocytic leukaemia
Michael Hallek et al.
LANCET (2018)
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
Colin E. Correnti et al.
LEUKEMIA (2018)
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Vanessa Buatois et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding
Leah V. Sibener et al.
CELL (2018)
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers et al.
HAEMATOLOGICA (2018)
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project
Saad Z. Usmani et al.
BLOOD CANCER JOURNAL (2018)
REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells
David J. Dilillo et al.
BLOOD (2018)
Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma
Youssef Hijazi et al.
CURRENT CLINICAL PHARMACOLOGY (2018)
A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma
Alexander M. Lesokhin et al.
BLOOD (2018)
CD3-Activating Bi-Specific Antibody Targeting CD19 on B Cells in Mono- and Bi-Valent Format
Yumin Cui et al.
BLOOD (2018)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Liqin Liu et al.
CLINICAL CANCER RESEARCH (2017)
Recombinant Expression of the Full-length Ectodomain of LDL Receptor-related Protein 1 (LRP1) Unravels pHdependent Conformational Changes and the Stoichiometry of Binding with Receptor- associated Protein ( RAP)
Camilla De Nardis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
S. Hipp et al.
LEUKEMIA (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
J. Duell et al.
LEUKEMIA (2017)
Immunotherapy with the trifunctional anti-CD20xanti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease
Anna Kieslich et al.
LEUKEMIA & LYMPHOMA (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
Elie Dheilly et al.
MOLECULAR THERAPY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jorg U. Schmohl et al.
CANCER RESEARCH AND TREATMENT (2017)
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
David Baker et al.
EBIOMEDICINE (2017)
PATHOBIOLOGY AND DIAGNOSIS OF MULTIPLE MYELOMA
Kevin Brigle et al.
SEMINARS IN ONCOLOGY NURSING (2017)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2017)
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Hanna A. Knaus et al.
CURRENT DRUG TARGETS (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka et al.
LEUKEMIA (2016)
Chronic lymphocytic leukaemia
Lydia Scarfo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Immunotherapeutic implications of IL-6 blockade for cytokine storm
Toshio Tanaka et al.
IMMUNOTHERAPY (2016)
Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma
Nicole C. Smits et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nanomedicine approaches in acute lymphoblastic leukemia
Andra-Sorina Tatar et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Targeting B-cell non Hodgkin lymphoma: New and old tricks
Antonio Giovanni Solimandoa et al.
LEUKEMIA RESEARCH (2016)
Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity
Andrew D. Tustian et al.
MABS (2016)
Adult Acute Lymphoblastic Leukemia
Shilpa Paul et al.
MAYO CLINIC PROCEEDINGS (2016)
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective
Jo Caers et al.
ONCOLOGIST (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
Judith Feucht et al.
ONCOTARGET (2016)
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Marco Ruella et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2016)
Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific 1-cell engager, in relapsed andfor refractory multiple myeloma (RRMM).
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Exploratory Pharmacokinetic/Pharmacodynamic and Tolerability Study of BCMAxCD3 in Cynomolgus Monkeys
Suzette Girgis et al.
BLOOD (2016)
CD20 Tcb (RG6026), a Novel 2:1 T Cell Bispecific Antibody for the Treatment of B Cell Malignancies
Marina Bacac et al.
BLOOD (2016)
Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy
Rajat Bannerji et al.
BLOOD (2016)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe et al.
BLOOD (2015)
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Giada Bianchi et al.
BLOOD (2015)
The double-edged sword: Neurotoxicity of chemotherapy
Rajiv S. Magge et al.
BLOOD REVIEWS (2015)
Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies
Veronika Bachanova et al.
CLINICAL CANCER RESEARCH (2015)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
Julia Stieglmaier et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Targeting B-cell maturation antigen in multiple myeloma
Yu-Tzu Tai et al.
IMMUNOTHERAPY (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Landscape of Tumor Antigens in T Cell Immunotherapy
Sadia Ilyas et al.
JOURNAL OF IMMUNOLOGY (2015)
Acute Lymphoblastic Leukemia, Version 2.2015
Joseph C. Alvarnas et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells
Uwe Reusch et al.
MABS (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Eric J. Smith et al.
SCIENTIFIC REPORTS (2015)
Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies
Gianfranco Pittari et al.
FRONTIERS IN IMMUNOLOGY (2015)
Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies
Friedhelm R. Schuster et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Timo Rath et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study
L. G. Lum et al.
BONE MARROW TRANSPLANTATION (2014)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Qunrui Ye et al.
CLINICAL CANCER RESEARCH (2014)
Toxicity management for patients receiving novel T-cell engaging therapies
David M. Barrett et al.
CURRENT OPINION IN PEDIATRICS (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system
C. Arndt et al.
LEUKEMIA (2014)
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
Uwe Reusch et al.
MABS (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Cancer-inducecd alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity
Anne-Sophie Chretien et al.
FRONTIERS IN IMMUNOLOGY (2014)
Diagnosis and Subclassification of Acute Lymphoblastic Leukemia
Sabina Chiaretti et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2014)
CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma
Lawrence G. Lum et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
Raymund Buhmann et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
N. Villamor et al.
LEUKEMIA (2013)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Aran F. Labrijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses
Andrea Biondi et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
Craig A. Portell et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Ching-Hon Pui et al.
BLOOD (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma
Johanna Atamaniuk et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2012)
Plasma Half-life Extension of Small Recombinant Antibodies by Fusion to Immunoglobulin-binding Domains
Meike Hutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Molecular pathogenesis of chronic lymphocytic leukemia
Gianluca Gaidano et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
Sebastian Boettcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Retargeting of Human Regulatory T Cells by Single-Chain Bispecific Antibodies
Stefanie Koristka et al.
JOURNAL OF IMMUNOLOGY (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
CD19 as an attractive target for antibody-based therapy
Ohad Hammer
MABS (2012)
DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes
Ofir Hakim et al.
NATURE (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
Roch Houot et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness
Davide Rossi et al.
BLOOD (2011)
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Prognostic factors in adult acute lymphoblastic leukaemia
Jacob M. Rowe
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia
Ulf Klein et al.
CANCER CELL (2010)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Efficient Inhibition of Human B-cell Lymphoma in SCID Mice by Synergistic Antitumor Effect of Human 4-1BB Ligand/Anti-CD20 Fusion Proteins and Anti-CD3/Anti-CD20 Diabodies
Rong Liu et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R. A. Kyle et al.
LEUKEMIA (2010)
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
Jonathan H. Davis et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives
Roland Stork et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy
Daniel A. Vallera et al.
LEUKEMIA RESEARCH (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels
Michael Stanglmaier et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
CD38 at the junction between prognostic marker and therapeutic target
Silvia Deaglio et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells
Freddy Tita-Nwa et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
Christian Brandl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases
B. Grzywacz et al.
LEUKEMIA (2007)
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma
T. Ise et al.
LEUKEMIA (2007)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia
Andrew G. Polson et al.
INTERNATIONAL IMMUNOLOGY (2006)
Species- and cell type-specific interactions between CD47 and human SIRPα
S Subramanian et al.
BLOOD (2006)
Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcγRIII (CD16)
J Bruenke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
BCMA is essential for the survival of long-lived bone marrow plasma cells
BP O'Connor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction:: Manifestation of a dual activation threshold
M Faroudi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors
M Sen et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
A Löffler et al.
BLOOD (2000)
Share Paper
